Talon Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

TLON 0.156
price chart
Spectrum Pharmaceuticals Acquires Talon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCQB:TLON) today announced that a subsidiary of Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI) entered into an agreement to purchase approximately 89% ...
Spectrum Acquires Talon - A Takeunder Case Study  Seeking Alpha
Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc. For $195 Million  Benzinga
Related articles »  
Talon Therapeutics Looks Undervalued Following FDA Approval
Shareholders of Talon Therapeutics (OTC: TLON) saw a pleasant surprise on August 9th when the FDA approved the company's flagship product, Marqibo, three days earlier than expected. The initial decision date under the PDUFA was on August 12th, ...
Related articles »  
Talon Therapeutics Announces $11M Financing
SAN MATEO, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has entered into an Investment Agreement with Warburg Pincus and Deerfield Management, its largest shareholders, for the sale of ...
Related articles »  
Talon Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Talon Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript. Apr. 1, 2013 4:30 PM ET | About: Talon Therapeutics, Inc. (TLON) by: SA Transcripts. Executives. Steven R. Deitcher - President and Chief Executive Officer. Craig W. Carlson ...
Related articles »  
Talon Therapeutics, Inc. (OTC:TLON) Falls Down on an Investor Update
Talon Therapeutics, Inc. (OTC:TLON, TLON message board) stock lost a large portion of its value in just two trading sessions last week.
Talon Therapeutics wins approval for leukemia drug
The generally accepted notion in the drug-development space is that it takes $1 billion or more and 10-plus years to bring a therapeutic to market.
Talon Wins US FDA Approval for Blood Cancer Treatment  Businessweek
Related articles »  
Hana Biosciences to Change Name to Talon Therapeutics
1, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, announced that its board of directors has approved changing its name to Talon Therapeutics, Inc. The ...
Related articles »  
Biotech Stock in Focus; Talon Therapeutics Inc. (TLON)
Commenting on the development, Steven R. Deitcher, MD, President and CEO of Talon Therapeutics, said that TLON believes Marqibo as part of a multi-drug treatment regimen has the potential to improve the outcomes for patients with newly diagnosed ...
Related articles »  
New Patent Issued for Talon Therapeutics' Marqibo(R) Expands Disease ...
SOUTH SAN FRANCISCO, Calif., March 10, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON), today announced the issuance of U.S.
Related articles »  
Talon Drops on FDA Review of Cancer Therapy: San Francisco Mover
Talon Therapeutics Inc. (TLON) fell the most since November 2010 after the U.S. Food and Drug Administration said it wants more time to review information about Talon's Marqibo blood-cancer treatment.
Related articles »